AIM: The aim of this study was to determine the prevalence, pattern and determinants of menstrual abnormalities in HIV-positive Nigerian women. METHODS: A cross-sectional study was carried out involving 3473 (2549 HIV-seropositive and 924 seronegative) consecutive and consenting women seen at the HIV treatment centers at the Nigerian Institute of Medical Research, Lagos and the Federal Medical Centre, Markurdi. RESULTS: The sociodemographic characteristics of the two groups were comparable, except for body mass index (BMI): the HIV-negative women (28.1 ± 8.1) had statistically significantly (P < 0.005) higher BMI compared to the HIV-positive women (21.9 ± 7.5). Menstrual abnormalities were significantly more common in women living with HIV/AIDS (29.1%) compared to the HIV-negative (18.9%) women (P < 0.001). The proportions of women in the two groups with intermenstrual bleeding, menorrhagia, hypermenorrhea, and postcoital bleeding were similar (P > 0.005), however amenorrhea, oligomenorrhea, irregular periods and secondary dysmenorrhea were more common in the HIV-positive women (P < 0.02). Primary dysmenorrhea was less common in HIV-positive women (P < 0.03). Among the HIV-positive women, menstrual dysfunction was more common in women living with HIV/AIDS with opportunistic infections, CD4 count < 200, not undertaking therapy, symptomatic disease and BMI < 20. However, after controlling for cofounders, only CD4 < 200 (odds ratio [OR], 3.65; 95% confidence interval [CI], 1.2-9.7), BMI < 20 (OR, 2.4; 95%CI, 1.3-3.5) and not taking antiretroviral drugs (OR, 2.05; CI, 1.7-6.5) were associated with amenorrhea, oligomenorrhea, irregular periods and secondary dysmenorrhea. CONCLUSION: HIV-positive women in this study experienced more menstrual abnormalities of amenorrhea, oligomenorrhea, and irregular periods compared to the HIV-negative controls. HIV-positive women with CD4 count < 200, BMI < 20 and who do not take antiretroviral drugs are at the greatest risk.
AIM: The aim of this study was to determine the prevalence, pattern and determinants of menstrual abnormalities in HIV-positive Nigerian women. METHODS: A cross-sectional study was carried out involving 3473 (2549 HIV-seropositive and 924 seronegative) consecutive and consenting women seen at the HIV treatment centers at the Nigerian Institute of Medical Research, Lagos and the Federal Medical Centre, Markurdi. RESULTS: The sociodemographic characteristics of the two groups were comparable, except for body mass index (BMI): the HIV-negative women (28.1 ± 8.1) had statistically significantly (P < 0.005) higher BMI compared to the HIV-positive women (21.9 ± 7.5). Menstrual abnormalities were significantly more common in women living with HIV/AIDS (29.1%) compared to the HIV-negative (18.9%) women (P < 0.001). The proportions of women in the two groups with intermenstrual bleeding, menorrhagia, hypermenorrhea, and postcoital bleeding were similar (P > 0.005), however amenorrhea, oligomenorrhea, irregular periods and secondary dysmenorrhea were more common in the HIV-positive women (P < 0.02). Primary dysmenorrhea was less common in HIV-positive women (P < 0.03). Among the HIV-positive women, menstrual dysfunction was more common in women living with HIV/AIDS with opportunistic infections, CD4 count < 200, not undertaking therapy, symptomatic disease and BMI < 20. However, after controlling for cofounders, only CD4 < 200 (odds ratio [OR], 3.65; 95% confidence interval [CI], 1.2-9.7), BMI < 20 (OR, 2.4; 95%CI, 1.3-3.5) and not taking antiretroviral drugs (OR, 2.05; CI, 1.7-6.5) were associated with amenorrhea, oligomenorrhea, irregular periods and secondary dysmenorrhea. CONCLUSION: HIV-positive women in this study experienced more menstrual abnormalities of amenorrhea, oligomenorrhea, and irregular periods compared to the HIV-negative controls. HIV-positive women with CD4 count < 200, BMI < 20 and who do not take antiretroviral drugs are at the greatest risk.
Authors: Angela M Bengtson; Daniel Westreich; Patrick Musonda; Audrey Pettifor; Carla Chibwesha; Benjamin H Chi; Bellington Vwalika; Brian W Pence; Jeffrey S A Stringer; William C Miller Journal: Epidemiology Date: 2016-09 Impact factor: 4.822
Authors: David G Dillon; Deepti Gurdasani; Johanna Riha; Kenneth Ekoru; Gershim Asiki; Billy N Mayanja; Naomi S Levitt; Nigel J Crowther; Moffat Nyirenda; Marina Njelekela; Kaushik Ramaiya; Ousman Nyan; Olanisun O Adewole; Kathryn Anastos; Livio Azzoni; W Henry Boom; Caterina Compostella; Joel A Dave; Halima Dawood; Christian Erikstrup; Carla M Fourie; Henrik Friis; Annamarie Kruger; John A Idoko; Chris T Longenecker; Suzanne Mbondi; Japheth E Mukaya; Eugene Mutimura; Chiratidzo E Ndhlovu; George Praygod; Eric W Pefura Yone; Mar Pujades-Rodriguez; Nyagosya Range; Mahmoud U Sani; Aletta E Schutte; Karen Sliwa; Phyllis C Tien; Este H Vorster; Corinna Walsh; Rutendo Zinyama; Fredirick Mashili; Eugene Sobngwi; Clement Adebamowo; Anatoli Kamali; Janet Seeley; Elizabeth H Young; Liam Smeeth; Ayesha A Motala; Pontiano Kaleebu; Manjinder S Sandhu Journal: Int J Epidemiol Date: 2013-12 Impact factor: 7.196
Authors: Shema Tariq; Hajra Okhai; Abigail Severn; Caroline A Sabin; Fiona Burns; Richard Gilson; Julie Fox; Yvonne Gilleece; Nicola E Mackie; Frank A Post; Iain Reeves; Melanie Rosenvinge; Ann Sullivan; Andrew Ustianowski; Robert F Miller Journal: HIV Med Date: 2021-11-17 Impact factor: 3.094
Authors: Monika Sarkar; Jennifer L Dodge; Ruth M Greenblatt; Mark H Kuniholm; Jack DeHovitz; Michael Plankey; Andrea Kovacs; Audrey L French; Eric C Seaberg; Igho Ofotokun; Margaret Fischl; Edgar Overton; Erin Kelly; Peter Bacchetti; Marion G Peters Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Christina Valiaveettil; Mona Loutfy; V Logan Kennedy; Sheila Caddy; Mark Yudin; Tracey Conway; Erin Ding; Paul Sereda; Alexandra de Pokomandy; Angela Kaida Journal: PLoS One Date: 2019-12-27 Impact factor: 3.240
Authors: Garazi Zulaika; Elizabeth Nyothach; Anna Maria van Eijk; David Obor; Linda Mason; Duolao Wang; Tao Chen; Emily Kerubo; Valarie Opollo; Isaac Ngere; Samuel Omondi Owino; Boaz Oyaro; Feiko O Ter Kuile; Daniel Kwaro; Penelope Phillips-Howard Journal: PLoS Med Date: 2021-09-28 Impact factor: 11.069